EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C14H21N3O3S |
| Net Charge | 0 |
| Average Mass | 311.407 |
| Monoisotopic Mass | 311.13036 |
| SMILES | Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1 |
| InChI | InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18) |
| InChIKey | OUDSBRTVNLOZBN-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Role: | potassium channel blocker An agent that inhibits cell membrane glycoproteins that are selectively permeable to potassium ions. |
| Application: | hypoglycemic agent A drug which lowers the blood glucose level. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| tolazamide (CHEBI:9613) has role hypoglycemic agent (CHEBI:35526) |
| tolazamide (CHEBI:9613) has role potassium channel blocker (CHEBI:50509) |
| tolazamide (CHEBI:9613) is a N-sulfonylurea (CHEBI:76983) |
| IUPAC Name |
|---|
| N-(azepan-1-ylcarbamoyl)-4-methylbenzenesulfonamide |
| INNs | Source |
|---|---|
| tolazamide | WHO MedNet |
| tolazamida | WHO MedNet |
| tolazamidum | WHO MedNet |
| tolazamide | WHO MedNet |
| Synonyms | Source |
|---|---|
| U 17835 | ChemIDplus |
| N-(p-toluenesulfonyl)-N'-hexamethyleniminourea | ChemIDplus |
| EINECS 214-588-3 | ChemIDplus |
| N-{[(hexahydro-1H-azepin-1-yl)-amino]carbonyl}-4-methylbenzenesulfonamide | ChemIDplus |
| BRN 1323565 | ChemIDplus |
| CCRIS 591 | ChemIDplus |
| Brand Names | Source |
|---|---|
| Tolinase | KEGG DRUG |
| Norglycin | ChemIDplus |
| Diabewas | ChemIDplus |
| Manual Xrefs | Databases |
|---|---|
| D00379 | KEGG DRUG |
| DB00839 | DrugBank |
| GB887886 | Patent |
| HMDB0014977 | HMDB |
| Tolazamide | Wikipedia |
| LSM-2699 | LINCS |
| 2694 | DrugCentral |
| Citations |
|---|